Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-NIS vs Chemotherapy in Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
NCT02364713Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2015
- Primary completion
- Jan 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of MV-NIS in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Mayo Clinic. Started Mar 2015; status: terminated.
02
Drugs
MV-NIS
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02364713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02364713.